SCHEDULE: Athira Pharma: Oliveira Group Reduces Stake Below 5%

Steven Michael Oliveira and affiliated entities have reduced their beneficial ownership in Athira Pharma, Inc. to 4.088% of common stock.

Summary

• Steven Michael Oliveira, Nemean Asset Management, LLC, and South Ocean Capital LLC collectively beneficially own 161,218 shares of Athira Pharma, Inc. common stock.
• This aggregate ownership represents 4.088% of the class of securities.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previous filing where ownership was likely above the 5% threshold.
• The reporting persons have shared voting and dispositive power over these 161,218 shares.
• South Ocean Capital Management LLC is also listed as a reporting person but holds 0 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in beneficial ownership by a significant institutional investor group to below 5%, which can be perceived as a negative signal regarding their conviction in the company.

Positives

• NA

Negatives

• The reduction in beneficial ownership by a significant institutional investor group to below the 5% threshold could be interpreted as a decrease in investment conviction or a partial divestment.

Risks

• A decrease in significant institutional ownership may signal perceived risks by the investor group regarding Athira Pharma's future performance or valuation.

Future Outlook

NA

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the reduction in beneficial ownership by a significant institutional investor group as a signal of decreased confidence in the company's future prospects, potentially influencing their investment decisions.

Key Dates

Recommendation

The reduction in beneficial ownership by a significant institutional investor group, falling below the 5% threshold, suggests a potential loss of confidence or a strategic divestment. This action by a sophisticated investor could signal underlying concerns about Athira Pharma's future performance or valuation, prompting a 'sell' recommendation for other investors to consider reducing their exposure.

Keywords

Athira Pharma, Beneficial Ownership, Schedule 13G, Common Stock, Steven Michael Oliveira, Nemean Asset Management, South Ocean Capital, Institutional Investor, SEC Filing